Engineering approaches to immunotherapy

Melody A. Swartz, Sachiko Hirosue, Jeffrey A. Hubbell

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

As the science of immunology grows increasingly mechanistic, motivation for developing quantitative, design-based engineering approaches has also evolved, both for therapeutic interventions and for elucidating immunological pathways in human disease. This has seeded the nascent field of "immunoengineering, " which seeks to apply engineering analyses and design approaches to problems in translational immunology. For example, cell engineers are creating ways to tailor and use immune cells as living therapeutics; protein engineers are devising new methods of rapid antibody discovery; biomaterials scientists are guiding vaccine delivery and immune-cell activation with novel constructs; and systems immunologists are deciphering the evolution and maintenance of T and B cell receptor repertoires, which could help guide vaccine design. The field is multidisciplinary and collaborative, with engineers and immunologists working together to better understand and treat disease. We discuss the scientific progress in this young, yet rapidly evolving research area, which has yielded numerous start-up companies that are betting on impact in clinical and commercial translation in the near future.

Original languageEnglish
Article number148rv9
JournalScience Translational Medicine
Volume4
Issue number148
DOIs
StatePublished - Aug 22 2012
Externally publishedYes

Fingerprint

Immunotherapy
Allergy and Immunology
Vaccines
Biocompatible Materials
T-Cell Antigen Receptor
B-Lymphocytes
Maintenance
Antibodies
Therapeutics
Research
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Engineering approaches to immunotherapy. / Swartz, Melody A.; Hirosue, Sachiko; Hubbell, Jeffrey A.

In: Science Translational Medicine, Vol. 4, No. 148, 148rv9, 22.08.2012.

Research output: Contribution to journalArticle

Swartz, Melody A. ; Hirosue, Sachiko ; Hubbell, Jeffrey A. / Engineering approaches to immunotherapy. In: Science Translational Medicine. 2012 ; Vol. 4, No. 148.
@article{3e69bf0ff3a94da892143458e120b7d6,
title = "Engineering approaches to immunotherapy",
abstract = "As the science of immunology grows increasingly mechanistic, motivation for developing quantitative, design-based engineering approaches has also evolved, both for therapeutic interventions and for elucidating immunological pathways in human disease. This has seeded the nascent field of {"}immunoengineering, {"} which seeks to apply engineering analyses and design approaches to problems in translational immunology. For example, cell engineers are creating ways to tailor and use immune cells as living therapeutics; protein engineers are devising new methods of rapid antibody discovery; biomaterials scientists are guiding vaccine delivery and immune-cell activation with novel constructs; and systems immunologists are deciphering the evolution and maintenance of T and B cell receptor repertoires, which could help guide vaccine design. The field is multidisciplinary and collaborative, with engineers and immunologists working together to better understand and treat disease. We discuss the scientific progress in this young, yet rapidly evolving research area, which has yielded numerous start-up companies that are betting on impact in clinical and commercial translation in the near future.",
author = "Swartz, {Melody A.} and Sachiko Hirosue and Hubbell, {Jeffrey A.}",
year = "2012",
month = "8",
day = "22",
doi = "10.1126/scitranslmed.3003763",
language = "English",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "148",

}

TY - JOUR

T1 - Engineering approaches to immunotherapy

AU - Swartz, Melody A.

AU - Hirosue, Sachiko

AU - Hubbell, Jeffrey A.

PY - 2012/8/22

Y1 - 2012/8/22

N2 - As the science of immunology grows increasingly mechanistic, motivation for developing quantitative, design-based engineering approaches has also evolved, both for therapeutic interventions and for elucidating immunological pathways in human disease. This has seeded the nascent field of "immunoengineering, " which seeks to apply engineering analyses and design approaches to problems in translational immunology. For example, cell engineers are creating ways to tailor and use immune cells as living therapeutics; protein engineers are devising new methods of rapid antibody discovery; biomaterials scientists are guiding vaccine delivery and immune-cell activation with novel constructs; and systems immunologists are deciphering the evolution and maintenance of T and B cell receptor repertoires, which could help guide vaccine design. The field is multidisciplinary and collaborative, with engineers and immunologists working together to better understand and treat disease. We discuss the scientific progress in this young, yet rapidly evolving research area, which has yielded numerous start-up companies that are betting on impact in clinical and commercial translation in the near future.

AB - As the science of immunology grows increasingly mechanistic, motivation for developing quantitative, design-based engineering approaches has also evolved, both for therapeutic interventions and for elucidating immunological pathways in human disease. This has seeded the nascent field of "immunoengineering, " which seeks to apply engineering analyses and design approaches to problems in translational immunology. For example, cell engineers are creating ways to tailor and use immune cells as living therapeutics; protein engineers are devising new methods of rapid antibody discovery; biomaterials scientists are guiding vaccine delivery and immune-cell activation with novel constructs; and systems immunologists are deciphering the evolution and maintenance of T and B cell receptor repertoires, which could help guide vaccine design. The field is multidisciplinary and collaborative, with engineers and immunologists working together to better understand and treat disease. We discuss the scientific progress in this young, yet rapidly evolving research area, which has yielded numerous start-up companies that are betting on impact in clinical and commercial translation in the near future.

UR - http://www.scopus.com/inward/record.url?scp=84865317394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865317394&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003763

DO - 10.1126/scitranslmed.3003763

M3 - Article

C2 - 22914624

AN - SCOPUS:84865317394

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 148

M1 - 148rv9

ER -